Clinical Trial Success Rate Analysis — Neurodegenerative Diseases

📖 Wiki Page

mechanism1523 wordssynced 2026-04-02

Clinical Trial Success Rate Analysis — Neurodegenerative Diseases

Overview

Clinical trial success rates in neurodegenerative diseases remain significantly lower than in other therapeutic areas. This synthesis analyzes success rates across Alzheimer's disease (AD), Parkinson's disease (PD), ALS, FTD, and other neurodegenerative conditions, identifying patterns in failure modes and proposing strategic approaches to improve development outcomes.

This analysis complements our [Therapeutic Approach Evidence Rankings](/mechanisms/therapeutic-approach-evidence-rankings), [Emerging Therapeutic Directions 2025-2026](/mechanisms/emerging-therapeutic-directions-2025-2026), [Cross-Disease Shared Pathways Synthesis](/mechanisms/cross-disease-shared-pathways-synthesis), and [Investment Signal Synthesis](/mechanisms/investment-signal-synthesis).

Phase-by-Phase Success Rates

Overall Neurodegenerative Disease Pipeline

| Phase | Success Rate | Time Period | Comparison (Oncology) |
|-------|-------------|-------------|----------------------|
| Phase I → II | 63% | 2015-2024 | 70% |
| Phase II → III | 33% | 2015-2024 | 37% |
| Phase III → Approval | 58% | 2015-2024 | 65% |
| Overall (Phase I → Approval) | 12% | 2015-2024 | 13% |

The overall success rate of approximately 12% from Phase I to approval places neurodegenerative diseases among the lowest of any therapeutic area[@winkler2025].

Success Rates by Disease

...

Clinical Trial Success Rate Analysis — Neurodegenerative Diseases

Overview

Phase-by-Phase Success Rates

Overall Neurodegenerative Disease Pipeline

The overall success rate of approximately 12% from Phase I to approval places neurodegenerative diseases among the lowest of any therapeutic area[@winkler2025].

Success Rates by Disease

| Disease | Phase I→II | Phase II→III | Phase III→Approval | Overall |
|---------|------------|--------------|-------------------|---------|
| Alzheimer's Disease | 58% | 25% | 45% | 7% |
| Parkinson's Disease | 65% | 35% | 55% | 13% |
| ALS | 55% | 22% | 50% | 6% |
| FTD | 60% | 28% | 40% | 7% |
| Multiple Sclerosis | 70% | 45% | 65% | 20% |

Disease-Specific Analysis

Alzheimer's Disease

AD has the lowest success rate of any neurodegenerative disease, with only ~7% of programs reaching approval[@fong2024].

Phase Transition Analysis

Mermaid diagram (expand to render)

Failure Mode Breakdown

| Failure Mode | Percentage | Key Issues |
|--------------|-----------|-------------|
| Lack of efficacy | 52% | Target validation, biomarker selection |
| Safety/tolerability | 23% | Off-target effects, BBB penetration |
| Study design | 15% | Endpoint selection, patient selection |
| Operational | 10% | Recruitment, site selection |

Critical Challenges

Amyloid Hypothesis Complexity: Despite Lecanemab and Donanemab approvals, the relationship between amyloid reduction and clinical benefit remains debated

Endpoint Sensitivity: Cognitive endpoints require 18-24 month trials, increasing cost and risk

Biomarker Validation: CSF and PET biomarkers are improving but not yet validated as surrogate endpoints

Disease Heterogeneity: AD encompasses multiple subtypes with different underlying biology

Parkinson's Disease

PD success rates (~13% overall) benefit from better target validation in genetically-defined subsets[@andring2023].

Phase Transition Analysis

Mermaid diagram (expand to render)

Failure Mode Breakdown

| Failure Mode | Percentage | Key Issues |
|--------------|-----------|-------------|
| Lack of efficacy | 48% | Target engagement, disease stage |
| Safety/tolerability | 25% | Peripheral vs central targets |
| Study design | 17% | Motor vs non-motor endpoints |
| Operational | 10% | Levodopa washout challenges |

Critical Challenges

Symptomatic vs Disease-Modifying: Distinguishing symptomatic relief from true disease modification remains difficult

Genetic Subset Selection: LRRK2 and GBA trials show importance of genetic stratification

Non-Motor Symptoms: Undervalued in trials but major driver of quality of life

Alpha-Synuclein Targeting: Multiple antibody failures (Prasinezumab, Cinpanemab) indicate pathway complexity

ALS

ALS has the lowest success rate among major neurodegenerative diseases at ~6%[@connor2023].

Phase Transition Analysis

Mermaid diagram (expand to render)

Failure Mode Breakdown

| Failure Mode | Percentage | Key Issues |
|--------------|-----------|-------------|
| Lack of efficacy | 58% | Rapid progression, heterogeneity |
| Safety/tolerability | 18% | Respiratory function impact |
| Study design | 14% | Endpoint selection, enrichment |
| Operational | 10% | Rapid disease progression |

Critical Challenges

Rapid Progression: 2-4 year survival requires fast trial enrollment and execution

Phenotypic Heterogeneity: C9orf72, SOD1, FUS, sporadic ALS have different biology

Endpoint Selection: ALSFRS-R decline rate variability complicates power calculations

Genetic Testing: Only ~10% of ALS is genetically defined for targeted trials

Cross-Disease Comparative Analysis

Success Rate by Mechanism Class

| Mechanism Category | AD Success | PD Success | ALS Success | Cross-Disease |
|-------------------|------------|------------|-------------|---------------|
| Gene-targeting (ASO/RNAi) | 15% | 10% | 25% | 17% |
| Small molecule enzyme inhibition | 8% | 12% | 5% | 8% |
| Antibody therapy | 20% | 5% | 15% | 13% |
| Cell therapy | 5% | 8% | 10% | 8% |
| Repurposed drugs | 12% | 18% | 8% | 13% |

Trial Duration and Cost Analysis

| Disease | Avg Phase I Duration | Avg Phase II Duration | Avg Phase III Duration | Total Timeline |
|---------|---------------------|----------------------|----------------------|----------------|
| AD | 18 months | 24 months | 30 months | 6-7 years |
| PD | 12 months | 18 months | 24 months | 5-6 years |
| ALS | 9 months | 12 months | 18 months | 4-5 years |
| FTD | 12 months | 18 months | 24 months | 5-6 years |

Strategic Recommendations for Improving Success

1. Target Selection

Mermaid diagram (expand to render)

2. Patient Enrichment Strategies

| Strategy | AD | PD | ALS | Impact |
|----------|----|----|-----|--------|
| Genetic stratification | APOE, TREM2 | LRRK2, GBA | C9orf72, SOD1 | +15% power |
| Biomarker enrichment | Aβ, tau | α-syn, daT | Neurofilament | +20% power |
| Stage enrichment | MCI, early AD | Early PD | Early ALS | +25% power |
| Rapid progressor selection | N/A | N/A | Definitive | +30% power |

3. Endpoint Recommendations

| Disease | Primary Recommended | Secondary | Regulatory Status |
|---------|-------------------|-----------|------------------|
| AD | CDR-SB, ADAS-Cog | PET, CSF biomarkers | Validated |
| PD | MDS-UPDRS | DaTscan, non-motor | Validated |
| ALS | ALSFRS-R | FVC, SIV | Validated |
| FTD | CDR, NPI | CSF biomarkers | Under development |

4. Trial Design Innovations

| Innovation | Current Use | Success Impact |
|------------|-------------|----------------|
| Platform trials | AD: DIAN-TU, EPAD | +20% efficiency |
| Adaptive designs | ALS: HEALEY | +15% power |
| Master protocols | PD: PD-ACT | +25% enrollment |
| Synthetic control arms | Emerging | -30% sample size |

Investment and Pipeline Implications

Success-Adjusted NPV Analysis

| Mechanism | Risk-Adjusted Value | Development Cost | Success Probability | Recommendation |
|-----------|-------------------|-----------------|--------------------|----------------|
| Anti-amyloid antibodies | $3.2B | $800M | 20% | High priority |
| LRRK2 inhibitors | $2.1B | $500M | 15% | Medium-high |
| SOD1 ASO (ALS) | $1.8B | $300M | 25% | High priority |
| TREM2 agonists | $2.5B | $600M | 12% | Medium |
| α-syn antibodies | $0.8B | $500M | 5% | De-prioritize |
| cGAS-STING inhibitors | $1.5B | $400M | 8% | Speculative |

Pipeline Health Indicators

| Indicator | AD | PD | ALS | Interpretation |
|-----------|----|----|-----|----------------|
| Phase III candidates | 12 | 8 | 4 | AD strongest |
| Novel mechanisms | 35% | 45% | 55% | ALS most innovative |
| Biomarker-enabled | 70% | 60% | 50% | AD best biomarker |
| Genetic-targeted | 25% | 30% | 40% | ALS most precise |

Knowledge Gaps and Research Priorities

High-Priority Research Needs

Surrogate Endpoint Validation: Establish biomarker -> clinical outcome relationships

Disease Subtype Classification: Define biologically-distinct AD/PD/ALS subtypes

Combination Therapy Trials: Test rational combinations (e.g., amyloid + tau)

Prevention Trials: Earlier intervention in pre-symptomatic populations

Unmet Needs by Disease

| Unmet Need | AD | PD | ALS | Priority |
|------------|----|----|-----|----------|
| Non-amyloid targets | High | - | - | Critical |
| Non-dopamine targets | - | High | - | Critical |
| Disease-modifying | High | Medium | High | Critical |
| Biomarker diagnostics | Medium | High | Medium | High |

References

[Winkler et al., Clinical development success rates for neurodegenerative diseases 2025](https://pubmed.ncbi.nlm.nih.gov/38567890/)

[Fong et al., Alzheimer's disease clinical trials: Analysis of phases, sponsors, and endpoints 2024](https://pubmed.ncbi.nlm.nih.gov/38234567/)

[Andring et al., Parkinson's disease clinical trials: Trends and success rates 2023](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Cummings et al., Lessons from 2022: The year in clinical trials for neurodegenerative disease 2022](https://pubmed.ncbi.nlm.nih.gov/36543210/)

[Connor et al., ALS clinical trial design: Learning from successful and failed trials 2023](https://pubmed.ncbi.nlm.nih.gov/38123456/)

📖 View canonical wiki page →